Medifast (MED) Cash & Current Investments (2010 - 2026)

Medifast (MED) has 17 years of Cash & Current Investments data on file, last reported at $168.9 million in Q1 2026.

• Quarterly Cash & Current Investments rose 2.64% year-over-year to $168.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168.9 million (up 2.64% YoY) and the FY2025 annual result came in at $167.3 million, up 3.04% from the prior year.
• Cash & Current Investments grew to $168.9 million in Q1 2026, from $167.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $173.5 million in Q3 2025 to a low of $61.1 million in Q2 2022.
• A 5-year average of $141.7 million and a median of $157.8 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 69.07% — and 2023, when it surged 141.37%.
• Tracing MED's Cash & Current Investments over 5 years: stood at $87.7 million in 2022, then jumped by 71.1% to $150.0 million in 2023, then advanced by 8.2% to $162.3 million in 2024, then grew by 3.04% to $167.3 million in 2025, then rose by 1.0% to $168.9 million in 2026.
• The last three Cash & Current Investments figures came in at $168.9 million (Q1 2026), $167.3 million (Q4 2025), and $173.5 million (Q3 2025), per Business Quant data.